CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day): Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)
- Population
- patients with schizophrenia
- Intervention
- CHLORPROMAZINE LOW DOSE (≤ 400 mg/day)
- Comparison
- MEDIUM DOSE (401 mg/day to 800 mg/day)
- Outcome
- Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: extrapyramidal symptoms (unspecified extrapyramidal… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day) Adverse effects: extrapyramidal symptoms (unspecified extrapyramidal symptoms ‐ short term) · people with schizophrenia CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: extrapyramidal symptoms (unspecified extrapyramidal… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty). Chlorpromazine dose for people with schizophrenia (2017) · Cochrane Headline outcomes only | RR 0.47 [0.3, 0.74] | 2 studies · 108 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chlorpromazine dose for people with schizophrenia 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.